Steven Artandi

Gao lab created an ML-guided workflow to deimmunize human protein domains for safer #GeneTherapy. They built zinc fingers and drug-controllable transcription factors to target genes like UTRN and SCN1A. www.sciencedirect.com/science/arti... @synbiogaolab.bsky.social‬ #AIandCancer

SCI member Claudia Petritsch & others found that immune checkpoint blockade, typically ineffective on its own in high-grade #glioma, can become a powerful treatment when combined with BRAF/MEK inhibition in BRAFV600E-mutant high-grade glioma. www.cell.com/cell-reports...

I am proud to share that U.S. News & World Report has ranked @StanfordHealth among the top ten #CancerHospitals in the nation. This ranking reflects our team's commitment to excellence across research, clinical innovation, and #PatientCare. med.stanford.edu/cancer/about... @usnews.com #CancerCare

SCI member Haruka Itakura and others developed an MRI-based model to predict survival risk in #TNBC patients, identifying high-risk groups with a 25% 5-year survival gap using a 50-gene signature. The tool showed strong accuracy and clinical potential. www.nature.com/articles/s41...

SCI member Edward Graves & others developed a method to enhance the effectiveness of hypoxia-targeted drugs in solid tumors.

SCI member Edgar Engleman & team found tumors use erythropoietin (EPO) to block immune attack. In #LiverCancer models, tumor EPO reprograms macrophages via EPOR to create a T cell-poor environment. Blocking the EPO/EPOR axis reactivates immunity & shrinks tumors. pubmed.ncbi.nlm.nih.gov/40273234/

SCI member Allison Kurian & others found that nearly half of #BreastCancer patients continue endocrine therapy beyond 5 years. The study emphasizes the importance of shared decision-making. academic.oup.com/jnci/advance...

Alexa Pohl & others found that transportation insecurity negatively impacted #BreastaCancerScreening, while social support positively affected colorectal and #BreastCancer screening. No interaction was found between social support and transportation insecurity. jamanetwork.com/journals/jam...

By uniting the innovative research efforts of Stanford Medicine and UCSF and drawing from the lessons of past successes, we can propel toward a future where cancer is no longer a formidable foe. @stanfordmedicine.bsky.social @ucsfcancer.bsky.social

Stanford postdoc Minji Jung & SCI members found #KidneyCancer survivors had a higher rate of depression and anxiety, especially during the early phase following diagnosis, compared with the noncancer population. aacrjournals.org/cebp/article...

Symptom-assessment intervention may improve care, reduce costs for older adults with cancer CHICAGO — A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve end-of-life care for older adults with cancer, according to data…

A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve #EndOfLifeCare for older adults with cancer, according to SCI member Manali Patel.

Post doc @jkim-1003.bsky.social & others found #AI natural language processing–enabled analysis of patient messages can generate valuable research topics that prioritize patient perspectives in #CancerCare, guiding future patient-centered health research. jamanetwork.com/journals/jam...

SCI member Sydney Lu & others found mutations in RNA splicing factors drive mis-spliced mRNA isoforms in cancers. They identified neoantigens from splicing alterations in #leukemia, showing TCR-engineered T cells target these mutations. pubmed.ncbi.nlm.nih.gov/40273911/

SCI member @johnleppert.bsky.social‬ & others review the challenge of managing small renal masses, urging caution over reflexive treatment. Drawing lessons from low-risk #ProstateCancer, they propose the TOP model to reduce overtreatment. pubmed.ncbi.nlm.nih.gov/40447472/

SCI member Paul Mischel & others found that #ecDNA drives evolution & heterogeneity in urothelial carcinoma, playing an early role in tumorigenesis. The study highlights immune evasion mechanisms linked to ecDNA, offering insights for developing targeted therapies. pubmed.ncbi.nlm.nih.gov/40331621/

CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.

Saurabh Dahiya showed 87% response and 78% complete remission in hard-to-treat #LBCL with low severe side effects. Early ASCO 2025 data suggest dual CD19/CD20 CAR-T could be a powerful new option. www.cgtlive.com/view/cd19-20... #ASCO25

SCI member Seung Kim & others found that stromal KITL in the pancreas restrains tumor progression. Downregulation of KITL during tumorigenesis promotes cancer. KITL signaling may offer potential for cancer prevention without disrupting tissue homeostasis. pubmed.ncbi.nlm.nih.gov/39918337/

SCI member Joel Neal & others found mobocertinib is not superior to platinum-based chemotherapy in treating EGFR ex20ins+ advanced/metastatic #NSCLC. No significant difference in progression-free survival, but mobocertinib showed longer response duration. pubmed.ncbi.nlm.nih.gov/39879577/

SCI member David Miklos & others report that allogeneic CD19 # CAR-T cells show 58% overall response and 42% complete response in CD19 CAR T-naïve patients with relapsed/refractory LBCL, with a manageable safety profile. pubmed.ncbi.nlm.nih.gov/39946666/ #LBCL"

Zhengyi Deng & others found excess weight and adult weight gain were associated with increased risk of #RenalCellCarcinoma (RCC), particularly ccRCC, whereas weight loss was associated with reduced risk. acsjournals.onlinelibrary.wiley.com/doi/abs/10.1...

SCI members Michael Longaker, Tushar Desai, Howard Chang, & others establish an atlas of pro- and anti-fibrotic factors that underlie lung matrix architecture and implicate fibroblast-associated biological features in modulating #fibrotic progression vs resolution. www.nature.com/articles/s41...

SCI member Irv Weissman & team introduce an engineered #macrophage approach for cancer therapy. Using eSPR tech, macrophages target tumor heterogeneity, resist polarization, & enhance CD8 T-cell responses. Suggests potential for improved #CancerImmunotherapy. pubmed.ncbi.nlm.nih.gov/40307254/

Stanford's Emma Lundberg & others create a global map of human subcellular architecture, revealing 275 molecular assemblies & unexpected roles for 975 proteins. Key discoveries include novel cancer proteins & insights into RNA processing & immune signaling. www.nature.com/articles/s41...

This program reflects our commitment to fostering meaningful partnerships and supporting the next generation of leaders in cancer research. We’re proud to be part of their journey and look forward to the ideas and energy they bring to our community this summer. @funchainmd.bsky.social

SCI members Julia Ransohoff & Allison Kurian & others found that most women with #BreastCancer who paused endocrine therapy for pregnancy did not restart treatment after having a child.

SCI members Kara Davis & others reveal that low IKAROS levels in B-ALL cells predict antigen escape after #CAR_T therapy. IKAROS^low cells lose B-cell identity, reducing CD19/CD22 expression and increasing therapy resistance. IKAROS may be key to preventing relapse. www.nature.com/articles/s41...

SCI member Robert Huang & others found major differences in #ColorectalCancer mortality among Asian American subgroups. Asian Indian Americans had the lowest rates; Korean Americans had the highest. Disaggregation by subgroup is essential for understanding risk.

‘Cure’ in Cancer: Should Oncologists Use the Word? Despite advances in treatments and improvements in survival overall, many oncologists remain hesitant to tell patients they’re cured.

SCI leader Pauline Funchain discusses the word "Cure." www.medscape.com/viewarticle/... @funchainmd.bsky.social

James Dickerson & others found current pricing makes trastuzumab deruxtecan not cost-effective for #HER2-low #MetastaticBreastCancer. A 41% price cut is needed for value-based care. Best sequencing? Use one antibody-drug conjugate—not both. ascopubs.org/doi/10.1200/... #BreastCancer

SCI leader @funchainmd.bsky.social & others review treatment strategies for #MetastaticMelanoma: BRAF/MEK inhibitors improve survival; #TILtherapy shows 30% durable response; novel TCR-T & CD3 bispecifics emerging; ICI viable even with irAEs, age, or transplant history.